PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION / ATTORNEY WORK PRODUCT
This memorandum was prepared by Calderwood & Harkness LLP at the request of and for the benefit of Penterra Pharmaceuticals Corp. and its affiliates. This memorandum constitutes a privileged and confidential attorney-client communication and attorney work product. It is protected from disclosure by the attorney-client privilege, the work product doctrine, and all other applicable privileges and protections. This memorandum should not be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.
CALDERWOOD & HARKNESS LLP Tax Department
Defense Strategy Memorandum
MEMORANDUM
FROM: Leonard Cross, Responsible Partner, Tax Department, Calderwood & Harkness LLP Sylvia Hartwell, Billing Partner, Tax Department, Calderwood & Harkness LLP
TO: Marcus Whitfield, Vice President of Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp. Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp.
DATE: July 12, 2022
RE: Comprehensive Defense Strategy — IRS Large Business & International Division Examination of Transfer Pricing, Tax Years 2017–2020 (Exam Team LB&I-NE-TP-2022-00641)
C&H Matter Number: 1018-00009
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to set forth Calderwood & Harkness LLP's ("C&H") comprehensive three-phase defense strategy for the Internal Revenue Service's ("IRS") transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC" or the "Company") covering Tax Years 2017 through 2020. This memorandum is intended to provide PPC management with a detailed roadmap of our recommended approach, an assessment of the anticipated exposure, and a clear framework for coordination among all advisors and stakeholders involved in the defense effort.
Background and Engagement. The IRS Large Business & International Division ("LB&I"), Northeast Transfer Pricing Practice, opened the current examination on May 16, 2022, as evidenced by Letter 2205-A issued to PPC on that date. C&H was formally engaged by PPC to represent the Company in this matter on June 2, 2022. On June 8, 2022, PPC filed IRS Form 2848 (Power of Attorney and Declaration of Representative) designating Leonard Cross, Sylvia Hartwell, Garrett Simmons, and Leila Nazari as authorized representatives before the IRS with respect to all matters arising from the examination. PPC was not enrolled in the IRS's Compliance Assurance Process ("CAP") for any of the tax years at issue, which means PPC did not have the benefit of pre-filing review and resolution of contested positions.
Scope of Examination. The examination is focused on PPC's intercompany arrangements with Penterra Biopharma International DAC ("PBI"), an Irish-resident subsidiary. Specifically, the IRS exam team is examining (i) the qualified cost-sharing arrangement ("CSA") effective July 1, 2012, under which PBI acquired the right to develop and exploit PPC's pharmaceutical intellectual property portfolio outside of the Americas in exchange for a platform contribution transaction ("PCT") payment and ongoing cost-sharing payments proportional to reasonably anticipated benefits, and (ii) the legacy IP royalty arrangement under which PBI pays PPC a 4.5% royalty on net sales of pre-2012 vintage compounds in non-Americas territories. The IRS may also challenge PBI's economic substance as an entity engaged in genuine commercial operations.
IRS Examination Team. The IRS has assembled a senior examination team for this matter, which is indicative of the significance the IRS attaches to PPC's transfer pricing arrangements. The team includes: Supervisory Revenue Agent Gerald Meskill (Team Manager), Lead Revenue Agent Patricia Dunleavy, IRS Economist Dr. Alan Washburne, Attorney-Advisor Franklin Rosario from the Office of Chief Counsel, and Senior Counsel Donna Hirabayashi. The involvement of an IRS economist and a Chief Counsel attorney at this stage signals the IRS's intention to mount a substantial transfer pricing challenge, and we should prepare accordingly.
Preliminary Assessment of Exposure. Based on our initial review of the examination scope, the pattern of the IRS's initial Information Document Requests ("IDRs"), and the composition of the exam team, we preliminarily assess that potential IRS adjustments could be substantial. The IRS may challenge the CSA cost-sharing ratios, assert that the 4.5% royalty rate on legacy compounds is below the arm's-length standard, question the adequacy of the $312 million PCT payment, and challenge PBI's economic substance. In aggregate, the potential proposed adjustments could reach a range of $350 million to $400 million if the IRS asserts its maximum positions across all issues. While we believe PPC's positions are well-supported and defensible, the magnitude of the potential exposure warrants a comprehensive and well-coordinated defense effort.
Three-Phase Defense Strategy. Our recommended defense strategy is organized into three sequential phases:
• Phase I: IDR Response and Information Management (June 2022 – Expected Fall 2023): This phase encompasses the comprehensive response to all IDRs issued by the IRS exam team, the development of the factual record, the commissioning and completion of economic analyses by our retained economic consultants, and the establishment of PBI's economic substance through documentary evidence.
• Phase II: NOPA Review and Formal Protest (Expected Fall 2023 – Winter 2023/2024): Upon issuance of a Notice of Proposed Adjustment ("NOPA"), this phase involves a thorough analysis of the IRS's proposed adjustments and the preparation and filing of a comprehensive formal Protest to secure PPC's right to an IRS Appeals conference.
• Phase III: IRS Appeals and Resolution (Expected Early–Mid 2024): This phase involves preparation for and participation in the IRS Appeals conference, hazards-of-litigation-based settlement negotiations, and the execution of a Closing Agreement or, if necessary, evaluation of Tax Court litigation.
Coordination Framework. The defense effort requires close coordination among multiple advisors and stakeholders. In addition to C&H, the engagement team includes Whitmore Valuation Group LLC ("Whitmore"), which has been retained as our economic consultants under a Kovel arrangement (letter executed June 20, 2022, reference 1018-00009-KV), ensuring that all communications between C&H, PPC, and Whitmore are protected by the attorney-client privilege. Dr. Helena Vasquez serves as Managing Director and Lead Economist, and Dr. Rohan Chakrabarti serves as Senior Director on the Whitmore team. Additionally, Thornbury & Keogh ("T&K"), Irish chartered tax advisors based in Dublin, serve as PBI's and PMI's Irish tax advisors and will provide critical support for documenting PBI's Irish operations and substance.
Objective. The overarching objective of this defense strategy is to defend PPC's transfer pricing positions as reflecting arm's-length pricing under IRC § 482 and the applicable Treasury Regulations, to minimize any proposed adjustment, to achieve full penalty abatement, and to resolve the examination at the administrative level without the need for Tax Court litigation. We are confident that PPC's transfer pricing positions are well-supported by the economic evidence, contemporaneous documentation, and applicable legal authority, and we intend to mount a vigorous defense.
II. Background — PPC's IP Structure and Intercompany Arrangements
A thorough understanding of PPC's corporate structure, intercompany arrangements, and operational facts is essential to the development and execution of our defense strategy. This Section provides a comprehensive overview of the relevant background.
A. Corporate Structure Overview
Penterra Pharmaceuticals Corp. ("PPC"). PPC is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA," and headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC's Employer Identification Number is 22-3741856. PPC is a specialty pharmaceutical and biotechnology company focused on three primary therapeutic areas: oncology, immunology, and rare-disease therapeutics. For fiscal year 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC employs approximately 14,500 individuals globally, with the majority of its research and development personnel and corporate functions based in the United States. PPC's senior leadership relevant to this engagement includes: Chief Executive Officer Catherine Falk, Chief Financial Officer Rajesh Iyer, General Counsel Deborah Staines, and Vice President of Global Tax Marcus Whitfield.
Penterra Holdings Luxembourg S.à r.l. ("PHL"). PHL is an intermediate holding company organized as a société à responsabilité limitée under the laws of the Grand Duchy of Luxembourg. PHL is registered at 14, rue Aldringen, L-1118 Luxembourg, and holds RCS (Registre de Commerce et des Sociétés) Number B 168452. PHL is 100% owned by PPC. For U.S. federal income tax purposes, PHL is treated as a disregarded entity under Treasury Regulation § 301.7701-3, meaning that its assets, liabilities, income, and deductions are treated as those of PPC for federal tax purposes. PHL's principal function is to serve as an intermediate holding entity in the ownership chain.
Penterra Biopharma International DAC ("PBI"). PBI is a designated activity company ("DAC") organized under the laws of Ireland. PBI is registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland, and holds Irish Tax Reference Number 3218764T. PBI is 100% owned by PHL. PBI's Managing Director is Aidan Naughton, who is based in Dublin and exercises substantive management authority over PBI's operations. PBI is the principal Irish operating entity in PPC's international structure and serves as the cost-sharing participant and licensee under the intercompany arrangements that are the subject of this examination. PBI's functions, assets, and risks are described in detail in Section II.D below.
Penterra Manufacturing Ireland Ltd. ("PMI"). PMI is a private limited company organized under the laws of Ireland, registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, and holding Companies Registration Office ("CRO") Number 512347. PMI is 100% owned by PBI. PMI operates as a contract manufacturer for PBI under a cost-plus transfer pricing arrangement, with a markup of cost plus 8%. PMI employs approximately 620 individuals at its Ringaskiddy manufacturing facility. PMI's transfer pricing arrangement with PBI is not, at present, a primary focus of the IRS examination, although PMI documents may be relevant to demonstrating PBI's operational substance and supply-chain management functions.
Ownership Chain. The ownership chain relevant to this examination is as follows:
PPC (Delaware) → PHL (Luxembourg, disregarded entity) → PBI (Ireland, DAC) → PMI (Ireland, Ltd.)
Because PHL is a disregarded entity for U.S. federal tax purposes, PPC is treated as the direct owner of PBI for purposes of the IRC § 482 analysis. This means that PPC and PBI are treated as "commonly controlled" entities subject to the IRS's allocation authority under § 482.
B. Cost-Sharing Arrangement (CSA)
PBI was incorporated on March 15, 2012, and the CSA between PPC and PBI was executed effective July 1, 2012. The CSA is governed by Treasury Regulation § 1.482-7, which sets forth the rules for qualified cost-sharing arrangements ("QCSAs") involving the development of intangible property by controlled participants.
Scope. Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical intellectual property portfolio outside the Americas (defined to include North America, Central America, South America, and the Caribbean) in exchange for two forms of consideration: (a) a one-time platform contribution transaction ("PCT") payment representing PBI's buy-in to PPC's pre-existing intellectual property portfolio, and (b) ongoing cost-sharing payments proportional to PBI's share of the reasonably anticipated benefits ("RABs") from the exploitation of developed intangibles.
PCT Payment. The PCT payment was a lump sum of $312 million, paid by PBI to PPC on July 1, 2012, representing the arm's-length value of PBI's buy-in to PPC's pre-existing IP portfolio, which at the time consisted primarily of clinical-stage and approved oncology compounds. The PCT valuation was prepared using a discounted cash flow ("DCF") income method at a weighted average cost of capital ("WACC") of 9.8%. Although the PCT payment relates to a transaction that occurred in 2012, outside the current examination years (TY 2017–2020), the adequacy of the PCT payment is relevant because the IRS may seek to use an alleged PCT undervaluation as a basis for recharacterizing the ongoing CSA cost-sharing ratios and royalty rates for the examination years.
Cost-Sharing Ratios. For the examination years, PBI's cost-sharing percentages were determined based on projected revenue splits between the Americas and non-Americas territories, which serve as the measure of RABs. The relevant cost-sharing data for each examination year is as follows:
The gradual increase in PBI's cost-sharing percentage reflects the growth of PPC's non-Americas business relative to its Americas business over the examination period, consistent with the global expansion of PBI's commercial operations and the maturation of PPC's product portfolio in non-Americas markets. PBI's cost-sharing percentages were updated annually based on actual and forecasted revenue data, in compliance with the RABs methodology prescribed by Treas. Reg. § 1.482-7.
C. Legacy IP Royalty Arrangement
In addition to the CSA, PPC and PBI maintain a separate intercompany license arrangement for legacy compounds — that is, pre-2012 vintage pharmaceutical products that were not included within the scope of the CSA. Under this legacy IP license, PBI pays PPC a royalty of 4.5% of net sales for the non-Americas territory. This royalty arrangement is governed by Treasury Regulation § 1.482-4, which sets forth the methods for determining arm's-length compensation for transfers of intangible property.
The relevant legacy compound royalty data for each examination year is as follows:
The declining trend in legacy compound net sales reflects the natural lifecycle of these mature pharmaceutical products, which face generic competition and declining prescription volumes in many non-Americas markets. This declining trajectory is significant because it further supports the reasonableness of the 4.5% royalty rate — a declining revenue base would not support a higher royalty rate under arm's-length principles, as a willing buyer would not agree to an increased royalty burden on a declining asset.
D. PBI's Functions, Assets, and Risks
PBI's functions, assets, and risks are central to the defense of PPC's transfer pricing positions. The IRS is expected to challenge PBI's economic substance, and our ability to demonstrate that PBI performs genuine, substantive functions in connection with the non-Americas exploitation of PPC's pharmaceutical IP will be critical.
Personnel and Headcount. PBI employs a dedicated workforce in Dublin, Ireland, with personnel performing regulatory affairs, medical affairs, commercial strategy, and supply-chain management functions. PBI's headcount has grown significantly since its incorporation, from 52 employees at the time of its establishment in 2012 to 185 employees by the end of 2020. This growth trajectory is indicative of a genuine operational build-out, not a static shell entity.
Commercial and Strategic Decision-Making. PBI bears genuine market risk for all non-Americas territories and makes key commercial decisions, including product pricing, market entry strategy, selection of distribution partners, and promotional strategy. PBI exercises independent pricing authority across 68 country markets in Europe, Asia-Pacific, the Middle East, Africa, and other non-Americas regions. These pricing decisions are made by PBI's commercial team in Dublin, under the oversight of Managing Director Aidan Naughton, and are documented in internal pricing memoranda and market-entry analyses.
Physical Presence. PBI occupies approximately 18,000 square feet of office space at its registered address at Sandyford Business Park, Dublin, Ireland. This physical presence is not merely nominal; it houses PBI's full complement of employees and serves as the operational headquarters for all non-Americas commercial activities.
Corporate Governance. During the examination period (2017–2020), PBI's Board of Directors held a total of 42 meetings, all conducted in Dublin. These meetings included regularly scheduled quarterly board meetings as well as special sessions convened to address product launches, regulatory developments, and strategic decisions. Board minutes and resolutions document substantive decision-making at each meeting.
Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the 2017–2020 period in connection with regulatory submissions for non-Americas territories. These expenditures reflect PBI's active role in obtaining and maintaining regulatory approvals in its licensed territories, including filings with the European Medicines Agency ("EMA"), national health authorities across Europe and Asia-Pacific, and other non-Americas regulatory bodies.
Banking and Financial Independence. PBI maintains independent banking operations with Glenmore Bank Ireland plc, including operating accounts, treasury management, and intercompany settlement accounts. PBI's financial affairs are managed by its own finance team in Dublin, not by PPC's treasury function in New Jersey.
Key Products and Revenue. PBI's non-Americas sales for the key products in 2020 were as follows:
PBI's total revenue for fiscal year 2020 was approximately €2.14 billion, with pre-tax income of approximately €1.06 billion.
Irish Tax Status. PBI claims Ireland's Knowledge Development box ("KDB") at an effective tax rate of 6.25% on qualifying IP income from fiscal year 2016 forward. Income not qualifying for the KDB is subject to the standard Irish trading rate of 12.5%. PBI's Irish tax compliance and advisory work is performed by Thornbury & Keogh, Chartered Tax Advisors, led by partner Ciarán Thornbury, with offices at 22 Fitzwilliam Square, Dublin 2, Ireland.
E. Contemporaneous Transfer Pricing Documentation
PPC maintained contemporaneous transfer pricing documentation for all four examination years (TY 2017, 2018, 2019, and 2020), as required for penalty-protection purposes under IRC § 6662(e). This documentation was originally prepared by Crestfield & Associates LLP ("Crestfield"), PPC's independent auditor and federal income tax return preparer. The engagement partner at Crestfield is Martin Ogilvy, and the transfer pricing partner is Susan Lam.
The contemporaneous documentation covers both the CSA methodology under Treas. Reg. § 1.482-7 (including the RABs-based cost-sharing ratios and the PCT valuation analysis) and the royalty methodology under Treas. Reg. § 1.482-4 (including the comparable uncontrolled transaction ("CUT") analysis supporting the 4.5% royalty rate). The documentation was prepared on a timely basis for each tax year and meets the standards set forth in IRC § 6662(e)(3)(B) and the applicable regulations.
PPC's Forms 1120 for Tax Years 2017, 2018, 2019, and 2020 are the returns at issue in the examination.
III. Anticipated IRS Positions and Exposure Analysis
Based on the opening conference, the initial IDR pattern, the composition of the IRS exam team, and our experience with similar examinations, this Section sets forth our assessment of the IRS's likely positions and PPC's corresponding exposure.
A. IRS's Likely Focus Areas Based on Opening Conference and Initial IDR Pattern
C&H conducted the opening conference with the IRS exam team on June 28, 2022, at the IRS's LB&I office. C&H was represented by Leonard Cross and Garrett Simmons, and PPC was represented by Marcus Whitfield. The IRS was represented by Supervisory Revenue Agent Gerald Meskill (Team Manager) and Lead Revenue Agent Patricia Dunleavy. Our notes from the opening conference, which are maintained in the C&H matter file, provide valuable insight into the IRS's focus areas and anticipated approach.
During the opening conference, the IRS exam team stated that the examination would focus on intercompany pricing between PPC and PBI, with particular attention to the following areas: (i) the PCT valuation and whether the $312 million payment adequately compensated PPC for the pre-existing IP transferred to PBI; (ii) the CSA cost-sharing percentages and whether PBI's share of qualified R&D costs is proportionate to PBI's reasonably anticipated benefits; (iii) the 4.5% royalty rate on legacy compounds and whether this rate is consistent with the arm's-length standard; and (iv) PBI's operational substance and whether PBI performs sufficient functions and bears sufficient risks to justify its role as an IP owner and CSA participant.
The involvement of IRS Economist Dr. Alan Washburne and Chief Counsel Attorney-Advisor Franklin Rosario at this early stage is a significant indicator. In our experience, the IRS does not deploy an economist and a Chief Counsel attorney to routine examinations. Their participation signals that the IRS has identified PPC's transfer pricing arrangements as a priority case and intends to mount a comprehensive challenge. We should expect Dr. Washburne to prepare an independent economic analysis of the CSA cost-sharing ratios, the legacy IP royalty rate, and potentially the PCT valuation, and we should expect Attorney-Advisor Rosario and Senior Counsel Hirabayashi to provide legal support for the development of the IRS's legal theories.
The IDR process has already commenced. Based on the scope of the examination and the IRS team's stated focus areas, we anticipate receiving between 40 and 50 IDRs over the next 12 to 15 months. A detailed IDR response strategy is set forth in Section V, Phase I, below.
B. PCT Undervaluation Risk
The IRS may assert that the $312 million PCT payment made by PBI to PPC on July 1, 2012, undervalued the pre-existing intellectual property that PBI acquired the right to exploit. The IRS's potential position would be that an income-method valuation using a lower discount rate and higher revenue projections could produce a PCT value significantly above $312 million — potentially in the range of $800 million or more.
Although the 2012 PCT is technically outside the examination years (TY 2017–2020), the IRS could use an alleged PCT undervaluation as a basis for recharacterizing the ongoing CSA cost-sharing ratios and royalty rates for the years under examination. Specifically, the IRS could argue that because PBI underpaid for the pre-existing IP, PBI's ongoing cost-sharing payments and royalty payments should be adjusted upward to compensate PPC for the shortfall. This theory, while legally debatable, has been employed by the IRS in prior transfer pricing examinations and cannot be dismissed.
Defense. C&H and Whitmore have prepared a DCF analysis using a WACC of 9.8%, which supports a PCT value within the arm's-length range of $278 million to $361 million. The $312 million PCT payment falls squarely within this range. The key point of dispute will be the appropriate discount rate. PPC's position is that a WACC of 9.8% is appropriate given the pharmaceutical-industry risk premiums, the beta of comparable pharmaceutical companies, and PBI-specific risk factors, including the risk associated with early-stage pharmaceutical IP and the uncertainty of non-Americas market development. We anticipate that the IRS will propose a significantly lower discount rate, potentially in the range of 7.0% to 7.5%, which would mechanically increase the PCT value by expanding the present value of projected cash flows. Whitmore is preparing a detailed technical analysis of the appropriate discount rate, including a comprehensive WACC derivation, for use in defending PPC's position.
C. CSA Cost-Sharing Ratio Adjustment Risk
The IRS is likely to propose increasing PBI's cost-sharing percentage by 8 to 12 percentage points across each examination year. The IRS's theory would be that PPC's projections of reasonably anticipated benefits understated the value of U.S.-source benefits, thereby allocating an insufficient share of total qualified R&D costs to PBI. Under this theory, PBI should have been paying a significantly larger share of the R&D costs, and the IRS would propose adjustments allocating additional income to PPC.
If the IRS prevails on this issue at its maximum proposed adjustment levels, the estimated additional cost-sharing payments to PPC could total approximately $200 million to $250 million across the four examination years. This represents the single largest component of the potential exposure.
Defense. PPC's methodology for projecting reasonably anticipated benefits was rigorous and complied in all material respects with Treas. Reg. § 1.482-7. The cost-sharing ratios were based on actual revenue data by territory and conservative growth assumptions, and the revenue splits between Americas and non-Americas territories were consistent across product lines. The IRS's proposed increases lack economic justification and would overstate U.S.-source benefits in a manner inconsistent with the actual and projected revenue distribution. Whitmore's CPM/TNMM analysis of 22 comparable companies confirms that PBI's operating margins are within the arm's-length interquartile range, providing an independent confirmation that PBI's overall compensation under the CSA is arm's-length.
D. Royalty Rate Challenge
The IRS is likely to assert that the 4.5% royalty rate on legacy IP is below the arm's-length standard and to propose an adjusted rate of 10% to 12%, based on IRS-selected CUT comparable transactions. If the IRS prevails on this issue, the estimated additional royalty income to PPC could total approximately $150 million to $200 million across the four examination years.
Defense. Whitmore's CUT analysis identifies 14 comparable pharmaceutical license agreements, with an interquartile range ("IQR") of 3.1% to 6.8% and a median of 4.4%. PPC's 4.5% royalty rate is virtually at the median and well within the IQR. The IRS's proposed rate of 10% to 12% (as anticipated based on our experience with similar cases) would far exceed the upper quartile of the comparable set and is likely based on non-comparable transactions that differ materially from PPC's legacy IP license in terms of the type of intangible, stage of development, risk allocation, and market coverage. Under the best method rule of Treas. Reg. § 1.482-1(d), the CUT method is the most reliable method for determining the arm's-length royalty rate in this case, and PPC's comparable selection is more rigorous than the comparables the IRS is likely to employ.
E. Economic Substance Challenge to PBI
The IRS may argue that PBI lacks sufficient economic substance to justify its role as IP owner and CSA participant, particularly given the significant income earned by PBI and the relatively low effective Irish tax rate resulting from the Knowledge Development box. The IRS's theory would be that the key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation) with respect to PPC's pharmaceutical IP remained predominantly in the United States, and that PBI served as little more than a conduit for channeling profits to a low-tax jurisdiction.
Defense. This argument is the IRS's weakest position, and we intend to rebut it forcefully. PBI maintains robust economic substance, as evidenced by:
• 185 employees in Dublin performing regulatory, commercial-strategy, supply-chain, and medical-affairs functions;
• 42 board meetings held in Dublin during 2017–2020, with documented substantive decision-making;
• €47.2 million in cumulative regulatory expenditures for non-Americas regulatory submissions;
• Independent pricing decisions across 68 country markets;
• Genuine market risk borne by PBI for non-Americas territories;
• Managing Director Aidan Naughton exercising real decision-making authority in Dublin;
• Independent banking operations at Glenmore Bank Ireland plc;
• Headcount growth from 52 (2012) to 185 (2020), demonstrating genuine operational build-out; and
• Approximately 18,000 square feet of office space at Sandyford Business Park.
PBI satisfies the DEMPE framework: it controls and funds Development (through its cost-sharing payments under the CSA), and it performs substantive Enhancement, Maintenance, Protection, and Exploitation activities for non-Americas IP rights through its Dublin-based team. We will compile a comprehensive substance dossier, including employee interviews, organizational charts, decision memos, and regulatory filing records, to present to the IRS exam team and, if necessary, to IRS Appeals.
F. Penalty Exposure
In connection with any proposed § 482 adjustments, the IRS may assert penalties under IRC § 6662(e) for substantial valuation misstatement, which imposes a 20% penalty on the underpayment attributable to the net § 482 allocation. The IRS may also reserve the right to assert the more severe IRC § 6662(h) gross valuation misstatement penalty (40%), although this is less likely to be asserted given the facts of this case.
Defense. PPC has a strong defense against the imposition of transfer pricing penalties. PPC maintained contemporaneous transfer pricing documentation for all four examination years, prepared by Crestfield & Associates, which meets the requirements of IRC § 6662(e)(3)(B). This contemporaneous documentation establishes that PPC's transfer pricing positions were supported by reasonable methodologies and professional economic analysis performed at the time the returns were filed. The reasonable-cause defense under the penalty provisions is strongly supported, and we are confident that penalty abatement should be achievable at any stage of the examination — whether during the exam phase, at IRS Appeals, or (if necessary) in Tax Court litigation.
The estimated penalty exposure, if the IRS's full adjustments were sustained and the 20% penalty were applied, would be calculated as 20% of the tax attributable to the adjustment amount. Given the magnitude of the potential adjustments, the penalty exposure could be meaningful, which further underscores the importance of maintaining PPC's penalty protection through the defense process.
G. Aggregate Preliminary Exposure Estimate
Based on the foregoing analysis, we present the following preliminary aggregate exposure estimate:
The tax impact of these proposed adjustments must be calculated with reference to the applicable corporate income tax rates. Tax Year 2017 is subject to a blended rate reflecting the transition from the pre-TCJA rate of 35% (for the portion of the year prior to January 1, 2018) and the post-TCJA rate of 21%. Tax Years 2018, 2019, and 2020 are subject to the 21% corporate rate enacted by the Tax Cuts and Jobs Act. The significant rate reduction from 35% to 21% effective January 1, 2018, substantially reduces the per-dollar tax exposure for TY 2018–2020 compared to TY 2017.
Additionally, the TCJA's Global Intangible Low-Taxed Income ("GILTI") provisions under IRC § 951A and the Base Erosion and Anti-Abuse Tax ("BEAT") provisions under IRC § 59A, both effective for TY 2018 and forward, may interact with any § 482 adjustments. Specifically, an increase in PPC's income and a corresponding decrease in PBI's income could affect PPC's GILTI inclusion computation and BEAT base erosion percentage calculation. These interactions will need to be modeled as part of any settlement analysis.
IV. Applicable Legal and Regulatory Framework
This Section outlines the principal legal and regulatory authorities that govern the transfer pricing issues in PPC's examination. A thorough understanding of this framework is essential for evaluating the strength of PPC's positions and anticipating the IRS's legal theories.
A. IRC § 482 — Arm's-Length Standard
Section 482 of the Internal Revenue Code provides the Secretary of the Treasury with broad authority to "distribute, apportion, or allocate gross income, deductions, credits, or allowances" among two or more organizations, trades, or businesses that are owned or controlled directly or indirectly by the same interests, "if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income" of any such organization, trade, or business. This is the foundational statutory provision underlying all transfer pricing adjustments in the United States.
The regulations under § 482, codified at Treas. Reg. §§ 1.482-1 through 1.482-9, establish the arm's-length standard as the fundamental principle governing intercompany pricing. Treas. Reg. § 1.482-1(b)(1) provides that "the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer." The regulations further prescribe specific methods for determining arm's-length compensation for various categories of transactions, including transfers of tangible property, intangible property, services, and cost-sharing arrangements.
The "best method rule" set forth in Treas. Reg. § 1.482-1(c) provides that the arm's-length result shall be determined under the method that, given the facts and circumstances, provides the most reliable measure of an arm's-length result. The selection of the best method is based on the degree of comparability between the controlled and uncontrolled transactions and the quality of the data and assumptions used in the analysis. This best method rule is critical to PPC's defense because it supports the use of the CUT method for the legacy IP royalty analysis (where high-quality comparable license agreements are available) and the income method for the PCT valuation.
Relevant case law on § 482 methodology includes numerous Tax Court and appellate decisions addressing cost-sharing arrangements, intangible property valuation, and the arm's-length standard. Of particular relevance to PPC's examination are decisions addressing the appropriate discount rate for income-method valuations, the selection of comparable transactions for CUT analyses, and the economic substance of foreign affiliates in the context of IP ownership structures. We will prepare detailed case analysis memoranda on the most relevant decisions, including those addressing cost-sharing and intangible property issues in the pharmaceutical industry, as part of our Phase I legal research program.
B. Treas. Reg. § 1.482-7 — Qualified Cost-Sharing Arrangements
Treasury Regulation § 1.482-7 governs qualified cost-sharing arrangements and sets forth the requirements that must be met for a CSA to be treated as a QCSA. These requirements include:
(a) The CSA must involve two or more controlled participants that share the costs and risks of intangible development activity in proportion to their reasonably anticipated benefits from the exploitation of the resulting intangibles.
(b) The CSA must provide for a platform contribution transaction ("PCT") payment if one participant contributes pre-existing intangibles or other resources that are reasonably anticipated to contribute to the development of cost-shared intangibles.
(c) The cost-sharing ratios must be based on the participants' respective shares of the reasonably anticipated benefits ("RABs") from the exploitation of the developed intangibles.
The regulation prescribes several methods for valuing PCT payments, including: (i) the income method, which values the PCT based on the present value of projected income attributable to the pre-existing intangibles; (ii) the market capitalization method; (iii) the acquisition price method; and (iv) the residual profit split method. PPC used the income method (DCF analysis) to value the PCT at $312 million, which we believe is the most appropriate and reliable method given the facts and circumstances.
The CSA cost-sharing ratio requirements are central to the IRS's anticipated challenge. The regulations require that each participant's share of intangible development costs be proportionate to that participant's share of the RABs from exploitation of the developed intangibles. The IRS's anticipated position — that PBI's share should be 8 to 12 percentage points higher than reported — would require a finding that PPC's RABs projections systematically understated non-Americas benefits, which we believe is not supported by the actual revenue data and market projections.
C. Treas. Reg. § 1.482-4 — Intangible Property / CUT Method
Treasury Regulation § 1.482-4 sets forth the methods for determining the arm's-length consideration for controlled transfers of intangible property. The available methods include: (i) the comparable uncontrolled transaction ("CUT") method; (ii) the comparable profits method ("CPM"); and (iii) the profit split method.
The CUT method, which PPC employed for the legacy IP royalty arrangement, determines the arm's-length royalty rate by reference to comparable transactions between uncontrolled parties. The regulation identifies specific comparability factors that must be considered, including the similarity of the intangible property, the contractual terms and conditions, the economic conditions, and the functional analysis of the parties. The CUT method is generally considered the most reliable method when sufficiently comparable transactions are available, and PPC's CUT analysis identifies 14 comparable pharmaceutical license agreements that provide a reliable basis for benchmarking the 4.5% royalty rate.
D. IRC § 367(d) — Outbound IP Transfer Considerations
Section 367(d) of the Code applies to outbound transfers of intangible property by U.S. persons to foreign corporations and requires the U.S. transferor to include in income, over the useful life of the intangible, amounts commensurate with the income attributable to the transferred intangible. The IRS may consider whether the CSA arrangement can be recharacterized as an outbound transfer of intangible property under § 367(d), which could provide an alternative legal theory for adjusting PPC's income.
The interplay between § 482 and § 367(d) is complex, and we will monitor whether the IRS pursues this alternative theory in addition to or in lieu of a direct § 482 challenge. If the IRS raises a § 367(d) argument, we will prepare a detailed rebuttal memorandum addressing the inapplicability of § 367(d) to a properly structured QCSA that complies with Treas. Reg. § 1.482-7.
E. IRC § 6662(e) — Transfer Pricing Penalty Regime
Section 6662(e) imposes a 20% penalty on any underpayment attributable to a "substantial valuation misstatement" arising from a § 482 allocation. A substantial valuation misstatement exists if the price for property or services (or for the use of property) is 200% or more (or 50% or less) of the amount determined under § 482. Section 6662(h) imposes a more severe 40% penalty for "gross valuation misstatements," which exist if the price is 400% or more (or 25% or less) of the § 482 amount.
Section 6662(e)(3)(B) provides a safe harbor from the substantial valuation misstatement penalty if the taxpayer (i) maintained contemporaneous documentation with respect to the transaction, and (ii) provided such documentation to the IRS within 30 days of a request. PPC maintained contemporaneous documentation prepared by Crestfield & Associates for all four examination years. In addition, the reasonable cause and good faith exception under § 6664(c) provides a general defense to accuracy-related penalties if the taxpayer can demonstrate that it had reasonable cause for its position and acted in good faith. PPC's reliance on professional economic analysis and the Crestfield contemporaneous documentation strongly supports a reasonable cause defense.
F. OECD Transfer Pricing Guidelines (2017, 2022 Revisions)
The Organisation for Economic Co-operation and Development ("OECD") Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations, including the 2017 edition and the 2022 revisions, are not binding authority for U.S. tax purposes but constitute persuasive authority that is frequently cited by the IRS, the Tax Court, and taxpayers in transfer pricing disputes. The OECD Guidelines provide a broadly consistent framework for analyzing transfer pricing issues across OECD member countries and are particularly relevant in cases involving cross-border arrangements with treaty partners.
Chapter VI of the OECD Guidelines, which addresses intangible property, is particularly relevant to PPC's examination. Chapter VI introduces the DEMPE framework (Development, Enhancement, Maintenance, Protection, and Exploitation), which provides an analytical approach for determining which entity in a multinational group should be treated as the economic owner of intangible property and is entitled to the returns from such property. The DEMPE framework focuses on which entity controls and performs the relevant functions, employs the relevant assets, and bears the relevant risks associated with each DEMPE function. We will use the DEMPE framework to support PBI's role as a genuine IP owner and CSA participant performing substantive DEMPE functions.
Chapter VIII of the OECD Guidelines addresses cost contribution arrangements (the OECD equivalent of the U.S. QCSA) and provides guidance on the valuation of buy-in payments and the determination of cost-sharing ratios that is broadly consistent with the approach taken under Treas. Reg. § 1.482-7.
G. U.S.-Ireland Income Tax Treaty
The Convention between the Government of the United States of America and the Government of Ireland for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital Gains (the "U.S.-Ireland Treaty") contains provisions that are relevant to PPC's examination.
Article 25 of the U.S.-Ireland Treaty provides for a mutual agreement procedure ("MAP") under which the competent authorities of the United States and Ireland shall endeavor to resolve, by mutual agreement, any difficulties or doubts arising as to the interpretation or application of the Treaty, including cases involving double taxation. If the IRS makes a § 482 adjustment that increases PPC's U.S. taxable income, and Ireland does not provide a corresponding adjustment to PBI's Irish taxable income, the result would be economic double taxation of the same income. In such circumstances, PPC (and/or PBI) may request competent authority assistance under Article 25 to obtain relief from double taxation.
We will evaluate the desirability and timing of a competent authority request as part of our Phase III resolution strategy, in coordination with Thornbury & Keogh on the Irish Revenue side.
V. Three-Phase Defense Plan
Phase I: IDR Response and Information Management (June 2022 – Expected Fall 2023)
A. Objectives. The objectives of Phase I are as follows:
1. Respond to all Information Document Requests issued by the IRS exam team in a manner that is accurate, complete, and protective of PPC's privileged information and attorney work product.
2. Shape the factual record produced to the IRS to support PPC's transfer pricing positions, including the reasonableness of the CSA cost-sharing ratios, the arm's-length nature of the 4.5% royalty rate, the adequacy of the PCT valuation, and PBI's economic substance.
3. Gather intelligence on the IRS exam team's focus areas, economic analysis direction, and anticipated legal theories through careful monitoring of IDR questions, document requests, and follow-up communications.
4. Establish PBI's economic substance through the comprehensive assembly and production of documentary evidence, including personnel records, board minutes, regulatory filings, pricing memoranda, and operational records.
B. IDR Response Strategy
C&H will implement a disciplined and structured IDR response process to ensure consistency, accuracy, and strategic alignment across all IDR responses.
Master IDR Tracker. Garrett Simmons, as the primary coordinator for IDR responses, will maintain a comprehensive master IDR tracker that logs all IDRs received, including the IDR number, date received, description of information requested, assigned C&H attorney or PPC contact, initial response deadline, any extension requests and dates, actual response date, documents produced, and any privileged documents withheld. We anticipate receiving between 40 and 50 IDRs over the course of the examination, and this tracker will serve as the central management tool for the document production process.
Primary Contacts. Garrett Simmons will serve as the primary coordinator for all IDR responses, with responsibility for drafting cover letters, reviewing produced documents, and coordinating with PPC's internal tax team. Leila Nazari will serve as the research and document production lead, with responsibility for managing the privilege review process, coordinating with T&K on Irish documentation, and maintaining the privilege log.
Review Process. Every IDR will be reviewed upon receipt for scope and privilege issues. If an IDR is overly broad, unduly burdensome, or seeks information protected by the attorney-client privilege or work product doctrine, C&H will assert appropriate objections in accordance with IRS IDR enforcement procedures. C&H will work cooperatively with the exam team to narrow the scope of disputed requests while protecting PPC's rights.
Template Cover Letter. A standardized template cover letter will be used for all IDR responses, addressed to Lead Revenue Agent Patricia Dunleavy, referencing Exam Team LB&I-NE-TP-2022-00641 and PPC EIN 22-3741856. Each cover letter will identify the IDR number, the documents produced, any documents withheld on privilege grounds, and any objections to the scope of the request.
Extension Requests. When necessary to ensure thorough and accurate responses, C&H will request reasonable extensions of IDR response deadlines. Requests will be made in writing to Revenue Agent Dunleavy in accordance with the IRS's IDR enforcement guidelines and will state the reasons for the requested extension.
C. Key Document Productions
Based on our assessment of the examination scope and anticipated IDR topics, the following key document productions are expected:
• IDR 1: Corporate structure and organizational charts for PPC and all relevant subsidiaries, including PHL, PBI, and PMI.
• IDR 2: The CSA agreement between PPC and PBI, effective July 1, 2012, together with all amendments, side letters, and modifications thereto.
• IDR 3: The legacy IP license agreement between PPC and PBI, together with all amendments and modifications.
• IDR 4: Contemporaneous transfer pricing documentation for Tax Years 2017 through 2020, as prepared by Crestfield & Associates.
• IDR 5: PCT valuation analysis and supporting workpapers, including the DCF model, revenue projections, WACC derivation, and all assumptions.
• IDR 6: R&D cost pool composition and allocation methodology for each examination year, including identification of qualified costs and the allocation of costs between CSA participants.
• IDR 7: PBI financial statements (both IFRS statutory accounts and management accounts) and Irish tax returns (Forms CT1) for the examination years.
• IDR 8: PBI personnel and headcount data, including organizational charts, employee lists with titles and functions, and year-over-year headcount changes.
• IDR 9: PBI board minutes and corporate governance documents for the examination years, including board resolutions, committee minutes, and governance policies.
• IDR 10: PMI contract manufacturing agreement with PBI, including cost-plus pricing terms and service-level specifications.
• IDR 11: Product revenue by territory for Veritaxol, Imvara, Cerulon, and all other products marketed by PBI, broken down by Americas and non-Americas territories.
• IDR 12: PBI office lease and physical presence documentation, including lease agreements, floor plans, and photographs of the Sandyford Business Park office.
• IDR 15: Regulatory expenditures and regulatory submissions for non-Americas territories, including filings with the EMA and national health authorities.
• IDR 18: Distribution agreements between PBI and third-party distributors in non-Americas territories.
• IDR 22: Glenmore Bank Ireland plc account records for PBI, including bank statements, signatory authorities, and treasury management policies.
• IDR 25: CUT comparable license agreements identified in PPC's transfer pricing documentation, including the terms and conditions of each comparable agreement.
• IDR 30: Knowledge Development box claims and supporting documentation filed with Irish Revenue, including qualifying IP income calculations.
• IDR 35: Intercompany pricing decisions and market strategy documents, including pricing memoranda, market-entry analyses, and commercial strategy presentations.
• IDR 40: Forms 5471 (Information Return of U.S. Persons with Respect to Certain Foreign Corporations) and other international informational returns for PBI and PHL for all examination years.
• IDR 44: PBI capital expenditure and investment records, including property, plant, and equipment schedules and capital budgets.
• Additional supplemental documentation as requested by the IRS exam team.
D. Privilege Protocol
The protection of privileged information is paramount throughout the examination process. C&H will maintain strict privilege protocols in accordance with Leonard Cross's privilege protocol memorandum dated June 10, 2022, which has been distributed to all members of the engagement team and to PPC's internal personnel involved in the examination.
Kovel Arrangement. Whitmore Valuation Group LLC has been retained under a Kovel arrangement, documented by the Kovel letter executed June 20, 2022 (reference 1018-00009-KV). Under this arrangement, all communications between C&H, PPC, and Whitmore relating to the examination are protected by the attorney-client privilege, provided that such communications are made for the purpose of facilitating the rendition of legal advice by C&H to PPC. The Kovel letter establishes that Whitmore has been retained as C&H's agent to assist in the provision of legal services, and that Whitmore's work product is being prepared at C&H's direction and under C&H's supervision. It is critical that all team members channel communications with Whitmore through C&H-directed communications to maintain the privilege.
Privilege Log. C&H will maintain a comprehensive privilege log for all documents withheld from production to the IRS on the basis of attorney-client privilege, work product doctrine, or any other applicable privilege or protection. The privilege log will identify each withheld document by date, author, recipient, general subject matter, and the basis for the privilege assertion.
Fact vs. Legal Analysis Distinction. In reviewing documents for production, the team must carefully distinguish between factual work product (which is generally producible) and legal analysis, strategy, and opinion work product (which is privileged and protected). Purely factual compilations, such as financial data, revenue reports, and organizational charts, are generally producible. However, documents reflecting C&H's legal analysis, strategy recommendations, or opinion work product must be withheld and logged.
Crestfield Coordination. Crestfield & Associates, as PPC's independent auditor and tax return preparer, is not counsel of record in this matter. Communications with Crestfield for the purpose of obtaining factual data (such as return data, workpapers, and R&D cost pool information) are not inherently privileged. However, communications with Crestfield that involve or reflect C&H's legal analysis should be channeled through C&H to preserve the privilege. Simmons will serve as the primary C&H point of contact for Crestfield coordination.
E. Coordination with Whitmore Valuation Group LLC
Whitmore Valuation Group LLC serves as C&H's retained economic consultants for this engagement. Dr. Helena Vasquez, Managing Director and Lead Economist, and Dr. Rohan Chakrabarti, Senior Director, are the principal contacts at Whitmore. All Whitmore work product is being prepared under the Kovel privilege arrangement at C&H's direction.
Scope of Work. Whitmore has been engaged to prepare the following economic analyses:
(a) A comprehensive functional analysis of PBI's operations, functions, assets, and risks in non-Americas territories;
(b) A benchmarking study using the CUT method (for the legacy IP royalty) and the CPM/TNMM method (for testing PBI's overall profitability);
(c) A PCT valuation analysis using the income method / DCF approach;
(d) A detailed WACC / Discount rate technical analysis supporting PPC's use of a 9.8% WACC; and
(e) Any rebuttal analysis necessary to respond to the IRS economist's (Dr. Washburne's) work product.
Billing. Whitmore's blended billing rate is $650 per hour. Total estimated Whitmore fees for the engagement are $1.5 million to $2.5 million.
Data Package. An initial data package was transmitted from C&H (Cross) to Whitmore (Dr. Vasquez) on June 21, 2022, following the engagement kickoff meeting. This data package includes the CSA agreement and amendments, the legacy IP license agreement, PBI and PPC financial statements, revenue data by territory and product, R&D cost pool data, and the Crestfield contemporaneous transfer pricing documentation.
Key Deliverables and Timeline. Whitmore's principal deliverables are expected between October and December 2022:
• CUT Analysis for Legacy IP Royalty (Target: October 2022): Identification and analysis of comparable pharmaceutical license agreements, computation of the IQR, and demonstration that PPC's 4.5% royalty rate falls within the arm's-length range.
• CPM/TNMM Analysis (Target: November 2022): Testing of PBI's operating margins against comparable distributors and IP-holding companies to confirm that PBI's overall profitability is within the arm's-length range.
• PCT DCF Valuation (Target: November 2022): Independent revaluation of the PCT payment using the income method at a WACC of 9.8%, confirming that the $312 million payment falls within the arm's-length range of $278 million to $361 million.
• WACC/Discount Rate Technical Analysis (Target: December 2022): Detailed derivation of the appropriate discount rate for the PCT valuation, including capital asset pricing model ("CAPM") inputs, beta analysis, equity risk premium, size premium, and PBI-specific risk factors.
F. Coordination with Thornbury & Keogh
Thornbury & Keogh ("T&K"), Chartered Tax Advisors, serves as PBI's and PMI's Irish tax compliance and advisory firm. The lead partner at T&K is Ciarán Thornbury, whose office is located at 22 Fitzwilliam Square, Dublin 2, Ireland.
T&K's role in the defense effort is to supply Irish-side documentation and substantive evidence supporting PBI's economic substance and Irish tax compliance. Specifically, T&K will provide:
• PBI's Irish Revenue filings, including Forms CT1 for the examination years;
• Knowledge Development box documentation and supporting calculations;
• Evidence of PBI's economic substance in Ireland, including descriptions of PBI's Irish operations and personnel;
• PBI's Irish statutory financial statements; and
• Any correspondence with Irish Revenue relevant to PBI's tax affairs.
Leila Nazari will serve as the primary C&H liaison with T&K. Initial coordination was established via email on August 12, 2022, and Nazari will manage the flow of documentation requests and responses between C&H and T&K throughout the engagement.
T&K's estimated fees for the engagement are approximately €312,500 (approximately $341,200 at estimated current exchange rates).
G. Coordination with Crestfield & Associates LLP
Crestfield & Associates LLP prepared the contemporaneous transfer pricing documentation and PPC's Forms 1120 for all four examination years. Simmons will coordinate with Crestfield's transfer pricing partner, Susan Lam, for the retrieval of original transfer pricing documentation, supporting workpapers, R&D cost pool data, return data, and any other factual materials required for the examination.
An initial data request was transmitted to Crestfield on July 10, 2022, and we anticipate ongoing coordination throughout Phase I as additional data needs are identified.
Crestfield does not appear as counsel of record in this matter. As noted above, communications with Crestfield for factual data are not inherently privileged, and all communications involving C&H legal analysis should be channeled through C&H to preserve privilege protections.